DK2799090T4 - Fremgangsmåde til fremstilling af en farmaceutisk kontrastmiddelformulering - Google Patents

Fremgangsmåde til fremstilling af en farmaceutisk kontrastmiddelformulering Download PDF

Info

Publication number
DK2799090T4
DK2799090T4 DK14165008.5T DK14165008T DK2799090T4 DK 2799090 T4 DK2799090 T4 DK 2799090T4 DK 14165008 T DK14165008 T DK 14165008T DK 2799090 T4 DK2799090 T4 DK 2799090T4
Authority
DK
Denmark
Prior art keywords
contractive
formulation
pharmaceutical
preparing
procedure
Prior art date
Application number
DK14165008.5T
Other languages
English (en)
Other versions
DK2799090T5 (da
DK2799090T3 (da
Inventor
Dominique Meyer
Claire Corot
Marc Port
Bruno Bonnemain
Vincent Barbotin
Original Assignee
Guerbet Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40955314&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2799090(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR0851055A external-priority patent/FR2927539B1/fr
Application filed by Guerbet Sa filed Critical Guerbet Sa
Application granted granted Critical
Publication of DK2799090T3 publication Critical patent/DK2799090T3/da
Publication of DK2799090T5 publication Critical patent/DK2799090T5/da
Publication of DK2799090T4 publication Critical patent/DK2799090T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Radiology & Medical Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK14165008.5T 2008-02-19 2009-02-18 Fremgangsmåde til fremstilling af en farmaceutisk kontrastmiddelformulering DK2799090T4 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0851055A FR2927539B1 (fr) 2008-02-19 2008-02-19 Procede de preparation d'une formulation pharmaceutique d'agents de contraste.
EP08154745 2008-04-17
US12/155,997 US20090208421A1 (en) 2008-02-19 2008-06-12 Process for preparing a pharmaceutical formulation of contrast agents
EP13154448.8A EP2591807A1 (en) 2008-02-19 2009-02-18 Process for preparing a pharmaceutical formulation of contrast agents

Publications (3)

Publication Number Publication Date
DK2799090T3 DK2799090T3 (da) 2016-10-03
DK2799090T5 DK2799090T5 (da) 2017-04-18
DK2799090T4 true DK2799090T4 (da) 2020-05-18

Family

ID=40955314

Family Applications (3)

Application Number Title Priority Date Filing Date
DK09712403.6T DK2242515T3 (da) 2008-02-19 2009-02-18 Fremgangsmåde til fremstilling af en farmaceutisk kontrastmiddelformulering
DK14165006.9T DK2799089T3 (da) 2008-02-19 2009-02-18 Fremgangsmåde til fremstilling af en farmaceutisk kontrastmiddelformulering
DK14165008.5T DK2799090T4 (da) 2008-02-19 2009-02-18 Fremgangsmåde til fremstilling af en farmaceutisk kontrastmiddelformulering

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK09712403.6T DK2242515T3 (da) 2008-02-19 2009-02-18 Fremgangsmåde til fremstilling af en farmaceutisk kontrastmiddelformulering
DK14165006.9T DK2799089T3 (da) 2008-02-19 2009-02-18 Fremgangsmåde til fremstilling af en farmaceutisk kontrastmiddelformulering

Country Status (17)

Country Link
US (6) US20090208421A1 (da)
EP (6) EP2799090B2 (da)
JP (3) JP5469615B2 (da)
KR (1) KR101063060B1 (da)
CN (1) CN101977633B (da)
BR (1) BRPI0908221B1 (da)
CA (1) CA2714118C (da)
CY (2) CY1115259T1 (da)
DE (1) DE202008010019U1 (da)
DK (3) DK2242515T3 (da)
ES (3) ES2597782T3 (da)
HR (2) HRP20140537T1 (da)
HU (2) HUE030219T2 (da)
LT (2) LT2799090T (da)
PL (3) PL2242515T3 (da)
PT (3) PT2799090T (da)
WO (1) WO2009103744A2 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090208421A1 (en) 2008-02-19 2009-08-20 Dominique Meyer Process for preparing a pharmaceutical formulation of contrast agents
FR2945448B1 (fr) 2009-05-13 2012-08-31 Guerbet Sa Procede de preparation d'une formulation pharmaceutique de chelate de lanthanide sous forme de poudre.
EP2338874A1 (en) 2009-12-16 2011-06-29 Bracco Imaging S.p.A Process for the preparation of chelated compounds
HUE051988T2 (hu) * 2013-01-07 2021-04-28 Univ Pennsylvania Készítmények és eljárások bõr T-sejt lymphoma kezelésére
TW201514188A (zh) * 2013-03-13 2015-04-16 Lantheus Medical Imaging Inc 製備釓磷維塞三鈉單水合物之方法
EP2786768A1 (en) 2013-04-04 2014-10-08 Agfa Healthcare Process for preparing a material comprising a macrocyclic ligand and for producing a pharmaceutical formulation comprising said ligand with a lanthanide
HUE033219T2 (en) 2013-04-26 2017-11-28 Guerbet Sa Contrast medium preparation and related preparation process
KR101466602B1 (ko) * 2013-05-31 2014-12-01 동국제약 주식회사 메글루민 가도테레이트를 포함하는 조영제 조성물의 제조방법
AT516104B1 (de) * 2014-07-31 2016-08-15 Sanochemia Pharmazeutika Ag Verfahren zum Herstellen einer flüssigen pharmazeutischen Zubereitung
KR101646211B1 (ko) * 2014-11-12 2016-08-05 (주)디아이테크 자기공명영상용 조영제의 제조방법
GB201421161D0 (en) * 2014-11-28 2015-01-14 Ge Healthcare As Metal complex formulations
GB201421163D0 (en) * 2014-11-28 2015-01-14 Ge Healthcare As Formulations of metal complexes
GB201421162D0 (en) * 2014-11-28 2015-01-14 Ge Healthcare As Lanthanide complex formulations
US20170035461A1 (en) * 2015-08-03 2017-02-09 Jeffery Deal Reversible tattoo colorant and method
DE102015013939A1 (de) * 2015-09-15 2017-03-16 be imaging GmbH Verfahren zur Herstellung von Gadotersäure (Gd-DOTA)- Komplexen
WO2017059092A1 (en) 2015-09-30 2017-04-06 Duke University Ascorbate formulations and methods of use as contrast agents
KR101625656B1 (ko) * 2015-10-16 2016-05-30 최경석 자기공명영상용 조영제의 제조방법
CN108289970B (zh) * 2015-11-30 2022-04-08 通用电气医疗集团股份有限公司 包含mri造影剂的组合的制剂
GB201610738D0 (en) 2016-06-20 2016-08-03 Ge Healthcare As Chelate compounds
WO2018069176A1 (en) 2016-10-12 2018-04-19 T2Pharma Gmbh Method of preparing formulations of lanthanide metal complexes of macrocyclic chelates
WO2018069179A1 (en) 2016-10-12 2018-04-19 T2Pharma Gmbh Method of preparing formulations of lanthanide metal complexes of macrocyclic chelates
EP3315141B1 (de) * 2016-10-28 2020-10-21 B.E. Imaging GmbH Verfahren zur herstellung von pharmazeutischen formulierungen enthaltend chelatkomplexe von gadolinium mit reduziertem gehalt an toxischen verunreinigungen
CN110035996B (zh) 2016-11-28 2022-08-09 拜耳医药股份公司 用于磁共振成像的新型高弛豫性钆螯合物
ES2813077T3 (es) 2016-12-21 2021-03-22 Ge Healthcare As Compuestos quelatos de manganeso basados en macrociclo de tetraazabiciclo adecuados como agentes de imagen de IRM
US20180185521A1 (en) * 2016-12-29 2018-07-05 Inventure, LLC Solvent-Free Gadolinium Contrast Agents
US20190269805A1 (en) * 2016-12-29 2019-09-05 Inventure, LLC Solvent-free gadolinium contrast agents
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
JP7191938B2 (ja) 2017-05-05 2022-12-19 センター・フォー・プローブ・デベロップメント・アンド・コマーシャライゼイション Ｉｇｆ－１ｒモノクローナル抗体及びその使用
RU2019139432A (ru) 2017-05-05 2021-06-07 Сентр фор Проуб Девелопмент энд Коммерсиализэйшн Фармакокинетическая оптимизация бифункциональных хелатов и их применение
WO2019020662A1 (de) * 2017-07-27 2019-01-31 Sanochemia Pharmazeutika Ag Zubereitung enthaltend ein kontrastmittel, und verfahren zum herstellen
FR3072281B1 (fr) * 2017-10-13 2020-12-04 Nh Theraguix Nanovecteurs et utilisations, en particulier pour le traitement de tumeurs
EP3728168B1 (en) 2017-12-20 2022-03-30 General Electric Company Anionic chelate compounds
AT521001B1 (de) * 2018-02-23 2020-10-15 Sanochemia Pharmazeutika Ag Herstellungsverfahren für ein Kontrastmittel
KR20210095168A (ko) 2018-11-23 2021-07-30 바이엘 악티엔게젤샤프트 조영 매체의 제형 및 그의 제조 방법
CN113939740A (zh) * 2019-01-03 2022-01-14 离子路径公司 用于离子束成像的组合物和试剂
FR3091873B1 (fr) * 2019-01-17 2020-12-25 Guerbet Sa Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de preparation et de purification
EP4048322A1 (en) * 2019-10-25 2022-08-31 Bracco Imaging SPA Pharmaceutical compositions of gd-based contrast agents
GB201919073D0 (en) 2019-12-20 2020-02-05 Ge Healthcare As Novel manufacturing process
TWI779284B (zh) * 2020-05-06 2022-10-01 商之器科技股份有限公司 用於影像資料標註的裝置
CA3181564A1 (en) 2020-06-10 2021-12-16 Ignacio Alonso Silva Procedure for obtaining gadoterate meglumine from high-purity tetraxetan (dota) and its use in the preparation of injectable galenical formulations
CN113801071B (zh) * 2021-09-14 2023-04-07 安徽普利药业有限公司 一种钆特酸葡甲胺的精制方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957939A (en) * 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
NL194579C (nl) * 1983-01-21 2002-08-05 Schering Ag Diagnostisch middel.
US4639365A (en) 1984-10-18 1987-01-27 The Board Of Regents, The University Of Texas System Gadolinium chelates as NMR contrast agents
US5082649A (en) 1987-06-30 1992-01-21 Mallinckrodt Medical, Inc. Method for enhancing the safety of metal-ligand chelates as magnetic resonance imaging agents by addition of calcium ions
FR2596992B1 (fr) * 1986-04-11 1988-12-16 Guerbet Sa Sel de lysine du complexe gadolinium-dota et ses applications au diagnostic
DE3640708C2 (de) * 1986-11-28 1995-05-18 Schering Ag Verbesserte metallhaltige Pharmazeutika
US5049667A (en) 1987-04-14 1991-09-17 Guerbet S.A. Nitrogen-containing cyclic ligands
WO1989000052A1 (en) * 1987-06-30 1989-01-12 Mallinckrodt, Inc. Method for enhancing the safety of metal-ligand chelates as magnetic resonants imaging agents and x-ray contrast agents
JP2854905B2 (ja) * 1988-09-27 1999-02-10 サリユーター・インコーポレイテツド キレート組成物
JPH02173483A (ja) 1988-12-23 1990-07-04 Komatsu Ltd 高速流量制御弁
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US4967447A (en) 1989-09-25 1990-11-06 Romaine Jeffrey L Fish slicer and method of frying fish
US5650133A (en) 1990-01-19 1997-07-22 Nycomed Salutar Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality
GB9000564D0 (en) 1990-01-10 1990-03-14 Dow Rheinmuenster Modified polyoxyethlene epoxy resin amphiphiles and stable aqueous epoxy dispersions thereof
GB9001245D0 (en) † 1990-01-19 1990-03-21 Salutar Inc Compounds
US7385041B2 (en) * 1990-04-25 2008-06-10 Bracco International B.V. Dual functioning excipient for metal chelate contrast agents
CA2039399C (en) 1990-04-25 2000-09-05 C. Allen Chang Dual functioning excipient for metal chelate contrast agents
CA2117775A1 (en) 1992-04-13 1993-10-28 Roberta C. Cheng Process for preparing macrocyclic chelating agents and formation of chelates and conjugates thereof
GB9318550D0 (en) 1993-09-07 1993-10-20 Nycomed Salutar Inc Chelants
FR2736051B3 (fr) * 1995-06-29 1997-09-26 Guerbet Sa Complexes metalliques de polyaminoacides, leur procede de preparation et leur utilisation en imagerie diagnostique
US5846517A (en) * 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
US7048907B2 (en) * 2001-02-05 2006-05-23 Biophysics Assay Laboratory, Inc. Synthesis, compositions and methods for the measurement of the concentration of stable-isotope labeled compounds in life forms and life form excretory products
TWI240632B (en) 2001-07-30 2005-10-01 Epix Medical Inc Purified peptides for peptide-based multimeric targeted contrast agents
JP2005534697A (ja) * 2002-08-06 2005-11-17 エピックス ファーマシューティカルズ， インコーポレイテッド ペプチド凝集体
WO2007002109A2 (en) 2005-06-20 2007-01-04 The Regents Of The University Of California Multidentate pyrone-derived chelators for medicinal imaging and chelation
EP1940841B9 (fr) 2005-10-07 2017-04-19 Guerbet Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
EP1993613A2 (en) 2006-03-15 2008-11-26 Mallinckrodt, Inc. Chelating conjugates having a substituted aromatic moiety and derivatives thereof
WO2007121453A2 (en) * 2006-04-17 2007-10-25 The Regents Of The University Of California 2-hydroxy-1-oxo 1,2 dihydro isoquinoline chelating agents
US20090208421A1 (en) 2008-02-19 2009-08-20 Dominique Meyer Process for preparing a pharmaceutical formulation of contrast agents

Also Published As

Publication number Publication date
EP2799090A2 (en) 2014-11-05
US20160235868A1 (en) 2016-08-18
EP2799090B1 (en) 2016-06-29
HUE031091T2 (en) 2017-06-28
US20160235867A1 (en) 2016-08-18
EP2799089B1 (en) 2016-08-03
ES2597782T3 (es) 2017-01-23
HRP20140537T1 (hr) 2014-07-18
US20170189563A1 (en) 2017-07-06
JP2014114306A (ja) 2014-06-26
HRP20161312T2 (hr) 2018-01-26
KR20100133976A (ko) 2010-12-22
EP2799090B2 (en) 2020-03-04
US20090208421A1 (en) 2009-08-20
BRPI0908221A2 (pt) 2018-03-20
EP3620179A1 (en) 2020-03-11
HUE030219T2 (en) 2017-04-28
ES2593127T3 (es) 2016-12-05
JP5985523B2 (ja) 2016-09-06
LT2799090T (lt) 2016-10-10
WO2009103744A3 (en) 2009-12-17
JP6422460B2 (ja) 2018-11-14
CN101977633A (zh) 2011-02-16
US9907866B2 (en) 2018-03-06
PL2242515T3 (pl) 2014-08-29
DK2242515T3 (da) 2014-07-07
ES2593127T5 (es) 2020-09-25
EP2242515A2 (en) 2010-10-27
PL2799090T5 (pl) 2020-07-13
JP2011514334A (ja) 2011-05-06
ES2593127T9 (es) 2017-05-08
ES2477541T3 (es) 2014-07-17
CN101977633B (zh) 2012-08-29
PL2799089T3 (pl) 2017-08-31
PT2799089T (pt) 2016-10-25
EP2591807A1 (en) 2013-05-15
BRPI0908221B1 (pt) 2021-07-13
PT2242515E (pt) 2014-07-11
CY1118985T1 (el) 2018-01-10
LT2799089T (lt) 2016-11-10
US20130336898A1 (en) 2013-12-19
US9636427B2 (en) 2017-05-02
EP2242515B9 (en) 2014-10-01
KR101063060B1 (ko) 2011-09-07
CA2714118A1 (en) 2009-08-27
DK2799089T3 (da) 2016-11-21
CA2714118C (en) 2017-03-28
JP5469615B2 (ja) 2014-04-16
WO2009103744A2 (en) 2009-08-27
EP2799090A3 (en) 2015-01-14
CY1115259T1 (el) 2017-01-04
EP2799089A3 (en) 2015-03-04
EP2242515B1 (en) 2014-04-02
DE202008010019U1 (de) 2009-07-02
EP2799089B9 (en) 2017-09-06
EP3159014A1 (en) 2017-04-26
JP2016117778A (ja) 2016-06-30
US20110129425A1 (en) 2011-06-02
EP2799089A2 (en) 2014-11-05
DK2799090T5 (da) 2017-04-18
PL2799090T3 (pl) 2017-08-31
US9655983B2 (en) 2017-05-23
DK2799090T3 (da) 2016-10-03
PT2799090T (pt) 2016-09-28
EP2799090B9 (en) 2016-12-21
HRP20161312T1 (hr) 2016-12-16

Similar Documents

Publication Publication Date Title
DK2242515T3 (da) Fremgangsmåde til fremstilling af en farmaceutisk kontrastmiddelformulering
DK2429486T3 (da) Fremgangsmåde til fremstilling af en tværbundet gel
DK2452281T3 (da) Fremgangsmåde til at forudsige virkningen af lægemidler i en patient
SMT201400069B (it) Formulazione farmaceutica
DK2346552T4 (da) Lægemiddelafgivelsesanordning og fremgangsmåde til fremstilling af en lægemiddelafgivelsesanordning
DK2649101T3 (da) Fremgangsmåde til fremstilling af en tværbundet gel
DK2467204T3 (da) Fremgangsmåde til fremstilling af en sorbent
DK3406337T3 (da) Fremgangsmåde til fremstilling af en hydrokrakningskatalysator
DK3061445T3 (da) Højkoncentrerede farmaceutiske formuleringer
DK3097925T3 (da) Farmaceutisk sammensætning
DK2345410T3 (da) Farmaceutisk sammensætning til modificeret frigivelse
DK2496562T3 (da) Fremgangsmåde til fremstilling af calcobutrol
BRPI1004940A2 (pt) composição farmacêutica
DK2118090T3 (da) Fremgangsmåde til fremstilling af et benzimidazolderivat
DK2149545T3 (da) Fremgangsmåde til fremstilling af en benzaldehydforbindelse
DK4159205T3 (da) Hidtil ukendt farmaceutisk sammensætning
BRPI1015939A2 (pt) composição farmacêutica
BRPI1012539A2 (pt) composições farmacêuticas
BRPI0921654A2 (pt) formulação farmacêutica
DK2391349T3 (da) Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
DK2424959T3 (da) Fremgangsmåde til fremstilling af en hydrokrakningskatalysator
IT1394400B1 (it) Composizioni farmaceutiche
BRPI0922653A2 (pt) preparação farmacêutica
DK2271618T3 (da) Farmaceutiske forbindelser
DK2450492T3 (da) Anlæg til fastgørelse af en sanitetsgenstand